The Pathogenic Transforming Growth Factor-β Overdrive Hypothesis in Aortic Aneurysms and Dissections
2017; Lippincott Williams & Wilkins; Volume: 120; Issue: 11 Linguagem: Inglês
10.1161/circresaha.116.310371
ISSN1524-4571
AutoresZiad Mallat, Hafid Aït-Oufella, Alain Tedgui,
Tópico(s)Blood Coagulation and Thrombosis Mechanisms
ResumoHomeCirculation ResearchVol. 120, No. 11The Pathogenic Transforming Growth Factor-β Overdrive Hypothesis in Aortic Aneurysms and Dissections Open AccessArticle CommentaryPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toOpen AccessArticle CommentaryPDF/EPUBThe Pathogenic Transforming Growth Factor-β Overdrive Hypothesis in Aortic Aneurysms and DissectionsA Mirage? Ziad Mallat, Hafid Ait-Oufella and Alain Tedgui Ziad MallatZiad Mallat From the Department of Medicine, Division of Cardiovascular Medicine, University of Cambridge, United Kingdom (Z.M.); and Institut National de la Santé et de la Recherche Médicale (Inserm) U970, Paris, France (Z.M., H.A.-O., A.T.). , Hafid Ait-OufellaHafid Ait-Oufella From the Department of Medicine, Division of Cardiovascular Medicine, University of Cambridge, United Kingdom (Z.M.); and Institut National de la Santé et de la Recherche Médicale (Inserm) U970, Paris, France (Z.M., H.A.-O., A.T.). and Alain TedguiAlain Tedgui From the Department of Medicine, Division of Cardiovascular Medicine, University of Cambridge, United Kingdom (Z.M.); and Institut National de la Santé et de la Recherche Médicale (Inserm) U970, Paris, France (Z.M., H.A.-O., A.T.). Originally published26 May 2017https://doi.org/10.1161/CIRCRESAHA.116.310371Circulation Research. 2017;120:1718–1720For >10 years ago, an unexpected role for the transforming growth factor-β cytokine pathway has been put forward in driving thoracic aortic aneurysms and dissections. Here, we reassess the evidence for a detrimental transforming growth factor-β overdrive in thoracic aortic aneurysms and dissections. In our view, most of the available mechanistic data argue against this theory.Syndromic thoracic aortic aneurysms and dissections (TAADs) develop in patients with connective tissue disorders because of genetic mutations that affect structural components of the extracellular matrix and the cell contractile machinery. Early pathogenic hypotheses attributed the aortopathy to structural failure of the aortic tissue. Over 14 years ago, Neptune et al,1 Habashi et al,2 and Lindsay and Dietz3 proposed a novel hypothesis to explain how fibrillin-1 (FBN1) mutations in Marfan syndrome (MFS) lead to pulmonary emphysema and aortic aneurysm and pointed to increased transforming growth factor-β (TGFβ) activation as the culprit mechanism. This constituted a major paradigm shift, and a new hope emerged that the life-threatening manifestations of MFS might be prevented by a simple medical treatment, losartan, shown to prevent the disease in mice through its TGFβ-antagonizing properties.2In 2010, we serendipitously discovered that TGFβ neutralization in mice treated with AngII (angiotensin II) unexpectedly induced fatal aortic dissections.4 Despite differences in the mouse models, the critical vasculoprotective role of TGFβ in our experiments highly contrasted with the reported pathogenic role of TGFβ in MFS and Loeys–Dietz syndrome (LDS), leading us to question the validity of the previous assumptions. Moreover, recent clinical testing of the concept in MFS patients failed to show any benefit of losartan over placebo or β-blockade.5 Thus, the time has come for a reassessment of the scientific evidence that supports a causal role for increased TGFβ signaling in TAADs.What Is the Evidence for Increased TGFβ Signaling in TAADs?Marfan SyndromeThe paradigm stipulates that FBN1 mutations are responsible for increased TGFβ signaling through increased bioavailability of TGFβ.FBN1 contains 8-cysteine domains similar to those found in LTBPs (latent TGFβ binding proteins) and directly interacts with LTBP1. An in vitro study showed that a recombinant FBN1 fragment (PF10) can interact with N-terminal FBN1 (which contains the hybrid domain required for binding to LTBP1) and inhibits its association with LTBP1.6 In cell layer extracellular matrix, PF10 releases endogenous TGFβ1, which stimulates SMAD2 phosphorylation (P-SMAD2). Because FBN1 mutations may increase proteolytic susceptibility of microfibrils, the above-described mechanism was proposed to account for increased TGFβ activity in MFS. However, those studies used engineered FBN1 fragments, which might not be relevant to FBN1 fragments generated in vivo. In fact, tissue-purified microfibrils did not increase P-SMAD2.6 Moreover, direct disruption of FBN1/LTBP interaction through deletion of the hybrid 1 region of FBN1 did not induce any MFS phenotype.7The strongest evidence for increased TGFβ activity in MFS seems to be (1) the demonstration of increased TGFβ signaling in the lungs of MFS mice using a GFP reporter under the control of TGFβ-responsive promoter elements1 and (2) the detection of a TGFβ signature (increased TGFβ ligands, P-SMAD2/3, and TGFβ-responsive genes) in MFS tissues.2 Yet, no evidence is available that the TGFβ reporter activity can be abrogated by an anti-TGFβ antibody. TGFβ-responsive promoter elements are SMAD3/SMAD4-binding sequences and may well respond to TGFβ-independent SMAD activation. This is likely given that increased activation of SMAD2/3 can occur independently of TGFβ in MFS tissues.8 Furthermore, the increased aortic TGFβ signature tends to occur in advanced stages of disease development, suggesting that it is a compensatory, rather than a primary, detrimental process. Indeed, aortic TGFβ signaling is unaltered in young Fbn1C1039G/+ MFS mice, despite the presence of early signs of aortic disease.9Mutations in the TGFβ Signaling PathwayLDS-associated mutations (TGFBR1, TGFBR2, TGFB2, TGFB3, SMAD3, and SMAD4) are expected to disrupt TGFβ signaling.3 However, this explanation has been challenged based on a tissue signature suggestive of increased TGFβ signaling.10 In fact, there is no evidence that this signature can be abrogated by neutralization of TGFβ. As in MFS, the TGFβ signature is detected only at late disease stages and is absent in aortas of young LDS animals.10 Moreover, vascular smooth muscle cells (VSMCs) from aortas of LDS mice displayed reduced, not increased, signaling in response to TGFβ.10Does Increased TGFβ Activity Promote TAADs?Marfan SyndromeNew data suggest that the original finding of reduced aortic aneurysm in Fbn1C1039G/+ MFS mice after TGFβ neutralization2 may not be reproducible. Cook et al11 found that treatment of Fbn1C1039G/+ mice with 1D11 anti-TGFβ antibody was associated with an appreciable trend toward disrupting (rather than preserving) aortic tissue architecture. 1D11 treatment also dramatically exacerbated the aortopathy in the severe Fbn1mgR/mgR model, when initiated at postnatal day 16.11 Intriguingly, the authors suggested an improvement in survival when 1D11 was initiated at day 45. However, the Kaplan–Meier curves indicate that the difference in survival was already present before the initiation of 1D11 injections, with survival curves being almost parallel after treatment initiation.Reduced aortopathy in Fbn1mgR/mgR mice under Ltbp3−/− background has been attributed to normalization of TGFβ activity.12 However, this is a speculation given that the authors were unable to detect differences in activity or signaling using antibodies that recognize either active TGFβ or phosphorylated SMADs in Ltbp3−/− mice.13Genetic manipulations of TGFβ signaling support a protective role of TGFβ in MFS. MFS aortopathy is aggravated in Fbn1C1039G/+ mice with disrupted canonical SMAD4 (Smad4+/−).14 This was interpreted as resulting from a detrimental increase of TGFβ-dependent noncanonical pathway.14 However, no data were presented to show that blockade of TGFβ abolishes the aortopathy of Fbn1C1039G/+Smad4+/− mice. In contrast, further reduction of TGFβ2 using Tgfb2+/− mice15 or deletion of Tgfbr2 in VSMCs9,16 substantially aggravated the aortopathy of Fbn1C1039G/+ mice.Mutations in the TGFβ Signaling PathwayIf TGFβ signaling is pathogenic in LDS, TGFβ neutralization should prevent the disease. However, treatment of Tgfbr2G357W/+ mice with 1D11 antibody failed to rescue the aortic phenotype.10 As in MFS, the disease was prevented by losartan, and treatment efficacy correlated with reduced TGFβ1 expression and P-SMAD2. However, losartan is not a selective TGFβ antagonist, and its protective effects in LDS (or MFS) mice cannot be used as a proof of the pathogenic role of TGFβ signaling in those settings. Actually, other studies strongly suggest that direct blockade of residual TGFβ signaling in LDS would be detrimental. Deletion of Tgfbr2 selectively in VSMCs (Myh11CreERT2Tgfbr2fl/fl) induces severe TAAD.16 Although the model is not a true LDS model, the phenotype is consistent with that of the Tgfbr2G357W/+ strain.10 Interestingly, TGFβ neutralization in Myh11CreERT2Tgfbr2fl/fl mice aggravated the disease and induced fatal aortic ruptures.16Other TAADsElastogenesis is altered in both Fibulin-4– and Fibulin-5–deficient mice. However, only Fibulin-4–deficient mice develop aortic aneurysm. In contrast to Fibulin-5, Fibulin-4 plays an additional role in targeting the enzyme lysyl oxidase (LOX) to microfibrils. Given the reported role of LOX in TGFβ inactivation, it has been argued that reduced LOX activity may be responsible for aortic aneurysm in Fibulin-4–deficient mice through increased TGFβ activation.3 However, neutralization of TGFβ signaling does not prevent the aortic disease of LOX-deficient embryos; it instead induces numerous hemorrhages.17 Thus, the aortic phenotype of LOX-deficient or Fibulin-4–deficient mice cannot be attributed to increased TGFβ signaling.Shprintzen–Goldberg syndrome is caused by mutations in SKI and shares features with MFS and LDS. Most of the mutations are missense mutations within the R-SMADs, suggesting a role for altered TGFβ signaling.18 Patient fibroblasts seem to display an increased TGFβ signature.18 However, the increased P-SMAD2/3 and P-ERK were seen in vitro in the absence of TGFβ, and intriguingly, responses to TGFβ2 stimulation (increase from baseline) were similar between the patient and control fibroblasts.18 Moreover, SKI knockdown does not necessarily impair TGFβ-dependent transcriptional responses,19 and there is currently no evidence that abrogation of TGFβ signaling rescues the phenotype of Shprintzen–Goldberg syndrome. Furthermore, SKI interacts with and regulates many other TGFβ-dependent or TGFβ-independent pathways.Does Lineage-Specific Variation in TGFβ Signaling Predispose to Aortopathy Through a Pathogenic TGFβ Overdrive?Two types of aortic SMCs are found in the ascending aorta: cardiac neural crest (CNC)–derived VSMCs and mesoderm second heart field (SHF)–derived VSMCs. CNC-derived VSMCs show increased sensitivity to TGFβ compared with SHF-derived VSMCs. Lindsay and Dietz3 built on these observations and developed a new hypothesis to embrace the paradox of high TGFβ signaling in TAADs. According to this hypothesis, SHF-derived VSMCs are more sensitive to an alteration of TGFβ signaling compared with CNC-derived VSMCs. Loss of TGFβ signaling in SHF-derived VSMCs would initiate compensatory events leading to increased expression/accumulation of TGFβ, which, in turn, could drive (excessive) signaling in CNC-derived VSMCs to induce aortopathy.3 Despite the apparent attractiveness of the hypothesis, there is no actual data to support it, and there are reasons to think that the hypothesis is not valid. In fact, the aortic phenotype of mice with selective deletion of Tgfbr2 in SHF-derived cells,20 cited in support of the hypothesis, is different from the aortic phenotype of mice with deletion of Tgfbr2 in all aortic VSMCs. Moreover, why would abrogation of TGFβ signaling in CNC-derived VSMCs on top of the already defective signaling in SHF-derived VSMCs (leading to abrogation of TGFβ signaling in all aortic root VSMCs) prevent the development of aortic disease? It should rather promote TAAD as described after deletion of Tgfbr2 signaling in all VSMC subsets.16ConclusionsFourteen years after the pathogenic TGFβ hypothesis, there is still insufficient evidence that MFS, LDS, or other TAADs are mediated by an overdrive of TGFβ signaling. In fact, most of the available data indicate that TGFβ is vasculoprotective in those settings.We think that the concept was based on 2 disputable interpretations. The first one has considered increased expression of P-SMAD2/3 and TGFβ-responsive gene products in diseased aortas as a pathognomonic signature of increased TGFβ signaling and a primary mechanism in disease pathogenesis, with little attention to any other plausible interpretation. The second one attributed the beneficial effect of losartan in mouse models of MFS and LDS to its TGFβ-antagonizing properties, not considering a large body of evidence that showed induction or aggravation of aortic aneurysm and dissection after direct inhibition of TGFβ activity or signaling.We think that strategies aimed at inhibition of TGFβ-dependent signaling are unlikely to provide any benefit to patients with TAADs and may even aggravate their disease. The time has come to abandon the unproven hypothesis of detrimental TGFβ overdrive in TAADs and explore new concepts and horizons.21,22Sources of FundingThis study was supported by British Heart Foundation, European Research Council, and Institut National de la Sante et de la Recherche Medicale.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to Ziad Mallat, Department of Medicine, Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom. E-mail [email protected]References1. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome.Nat Genet. 2003; 33:407–411. doi: 10.1038/ng1116.CrossrefMedlineGoogle Scholar2. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.Science. 2006; 312:117–121. doi: 10.1126/science.1124287.CrossrefMedlineGoogle Scholar3. Lindsay ME, Dietz HC. Lessons on the pathogenesis of aneurysm from heritable conditions.Nature. 2011; 473:308–316. doi: 10.1038/nature10145.CrossrefMedlineGoogle Scholar4. Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, Taleb S, Huang J, Offenstadt G, Combadière C, Rénia L, Johnson JL, Tharaux PL, Tedgui A, Mallat Z. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice.J Clin Invest. 2010; 120:422–432. doi: 10.1172/JCI38136.CrossrefMedlineGoogle Scholar5. Lacro V, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan's syndrome.N Engl J Med. 2014; 371:2061–2071.CrossrefMedlineGoogle Scholar6. Chaudhry SS, Cain SA, Morgan A, Dallas SL, Shuttleworth CA, Kielty CM. Fibrillin-1 regulates the bioavailability of TGFbeta1.J Cell Biol. 2007; 176:355–367. doi: 10.1083/jcb.200608167.CrossrefMedlineGoogle Scholar7. Charbonneau NL, Carlson EJ, Tufa S, Sengle G, Manalo EC, Carlberg VM, Ramirez F, Keene DR, Sakai LY. In vivo studies of mutant fibrillin-1 microfibrils.J Biol Chem. 2010; 285:24943–24955. doi: 10.1074/jbc.M110.130021.CrossrefMedlineGoogle Scholar8. Gomez D, Kessler K, Michel JB, Vranckx R. Modifications of chromatin dynamics control Smad2 pathway activation in aneurysmal smooth muscle cells.Circ Res. 2013; 113:881–890. doi: 10.1161/CIRCRESAHA.113.301989.LinkGoogle Scholar9. Wei H, Hu JH, Angelov S, Fox K, Yan J, Enstrom R, Smith A, Dichek DA. Aortopathy in a mouse model of Marfan syndrome is not mediated by altered transforming growth factor beta signaling.J Am Heart Assoc. 2016;In press.Google Scholar10. Gallo EM, Loch DC, Habashi JP, et al. Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis.J Clin Invest. 2014; 124:448–460. doi: 10.1172/JCI69666.CrossrefMedlineGoogle Scholar11. Cook JR, Clayton NP, Carta L, Galatioto J, Chiu E, Smaldone S, Nelson CA, Cheng SH, Wentworth BM, Ramirez F. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.Arterioscler Thromb Vasc Biol. 2015; 35:911–917. doi: 10.1161/ATVBAHA.114.305150.LinkGoogle Scholar12. Zilberberg L, Phoon CK, Robertson I, Dabovic B, Ramirez F, Rifkin DB. Genetic analysis of the contribution of LTBP-3 to thoracic aneurysm in Marfan syndrome.Proc Natl Acad Sci USA. 2015; 112:14012–14017. doi: 10.1073/pnas.1507652112.CrossrefMedlineGoogle Scholar13. Dabovic B, Chen Y, Colarossi C, Obata H, Zambuto L, Perle MA, Rifkin DB. Bone abnormalities in latent TGF-beta binding protein (Ltbp)-3-null mice indicate a role for Ltbp-3 in modulating TGF-beta bioavailability.J Cell Biol. 2002; 156:227–232.CrossrefMedlineGoogle Scholar14. Holm TM, Habashi JP, Doyle JJ, et al. Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.Science. 2011; 332:358–361. doi: 10.1126/science.1192149.CrossrefMedlineGoogle Scholar15. Lindsay ME, Schepers D, Bolar NA, et al. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm.Nat Genet. 2012; 44:922–927. doi: 10.1038/ng.2349.CrossrefMedlineGoogle Scholar16. Li W, Li Q, Jiao Y, Qin L, Ali R, Zhou J, Ferruzzi J, Kim RW, Geirsson A, Dietz HC, Offermanns S, Humphrey JD, Tellides G. Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis.J Clin Invest. 2014; 124:755–767. doi: 10.1172/JCI69942.CrossrefMedlineGoogle Scholar17. Kutchuk L, Laitala A, Soueid-Bomgarten S, Shentzer P, Rosendahl AH, Eilot S, Grossman M, Sagi I, Sormunen R, Myllyharju J, Mäki JM, Hasson P. Muscle composition is regulated by a Lox-TGFβ feedback loop.Development. 2015; 142:983–993. doi: 10.1242/dev.113449.CrossrefMedlineGoogle Scholar18. Doyle AJ, Doyle JJ, Bessling SL, et al. Mutations in the TGF-β repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm.Nat Genet. 2012; 44:1249–1254. doi: 10.1038/ng.2421.CrossrefMedlineGoogle Scholar19. Javelaud D, van Kempen L, Alexaki VI, Le Scolan E, Luo K, Mauviel A. Efficient TGF-beta/SMAD signaling in human melanoma cells associated with high c-SKI/SnoN expression.Mol Cancer. 2011; 10:2. doi: 10.1186/1476-4598-10-2.CrossrefMedlineGoogle Scholar20. Choudhary B, Zhou J, Li P, Thomas S, Kaartinen V, Sucov HM. Absence of TGFbeta signaling in embryonic vascular smooth muscle leads to reduced lysyl oxidase expression, impaired elastogenesis, and aneurysm.Genesis. 2009; 47:115–121. doi: 10.1002/dvg.20466.CrossrefMedlineGoogle Scholar21. Humphrey JD, Schwartz MA, Tellides G, Milewicz DM. Role of mechanotransduction in vascular biology: focus on thoracic aortic aneurysms and dissections.Circ Res. 2015; 116:1448–1461. doi: 10.1161/CIRCRESAHA.114.304936.LinkGoogle Scholar22. Mallat Z, Tedgui A, Henrion D. Role of Microvascular Tone and Extracellular Matrix Contraction in the Regulation of Interstitial Fluid: Implications for Aortic Dissection.Arterioscler Thromb Vasc Biol. 2016; 36:1742–1747. doi: 10.1161/ATVBAHA.116.307909.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Toral M, Fuente‐Alonso A, Campanero M and Redondo J (2021) The NO signalling pathway in aortic aneurysm and dissection, British Journal of Pharmacology, 10.1111/bph.15694, 179:7, (1287-1303), Online publication date: 1-Apr-2022. Abrial M, Basu S, Huang M, Butty V, Schwertner A, Jeffrey S, Jordan D, Burns C and Burns C (2022) Latent TGFβ-binding proteins 1 and 3 protect the larval zebrafish outflow tract from aneurysmal dilatation, Disease Models & Mechanisms, 10.1242/dmm.046979, 15:3, Online publication date: 1-Mar-2022. Rodrigues-Díez R, Tejera-Muñoz A, Esteban V, Steffensen L, Rodrigues-Díez R, Orejudo M, Rayego-Mateos S, Falke L, Cannata-Ortiz P, Ortiz A, Egido J, Mallat Z, Briones A, Bajo M, Goldschmeding R and Ruiz-Ortega M (2021) CCN2 (Cellular Communication Network Factor 2) Deletion Alters Vascular Integrity and Function Predisposing to Aneurysm Formation, Hypertension, 79:3, (e42-e55), Online publication date: 1-Mar-2022. Bertani F, Fuggirai A and Boccafoschi F (2022) Is pathology useful in vascular surgery? Vascular Surgery, 10.1016/B978-0-12-822113-6.00002-4, (1-9), . Tejera-Muñoz A, Marquez-Exposito L, Tejedor-Santamaría L, Rayego-Mateos S, Orejudo M, Suarez-Álvarez B, López-Larrea C, Ruíz-Ortega M and Rodrigues-Díez R (2021) CCN2 Increases TGF-β Receptor Type II Expression in Vascular Smooth Muscle Cells: Essential Role of CCN2 in the TGF-β Pathway Regulation, International Journal of Molecular Sciences, 10.3390/ijms23010375, 23:1, (375) van Dorst D, de Wagenaar N, van der Pluijm I, Roos-Hesselink J, Essers J and Danser A (2020) Transforming Growth Factor-β and the Renin-Angiotensin System in Syndromic Thoracic Aortic Aneurysms: Implications for Treatment, Cardiovascular Drugs and Therapy, 10.1007/s10557-020-07116-4, 35:6, (1233-1252), Online publication date: 1-Dec-2021. Arun D, Munir W, Schmitt L, Vyas R, Ravindran J, Bashir M, Williams I, Velayudhan B and Idhrees M (2021) Exploring the Correlation and Protective Role of Diabetes Mellitus in Aortic Aneurysm Disease, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2021.769343, 8 Tehrani A, Ciufolini M and Bernatchez P (2021) Nitric oxide in the Marfan vasculature: Friend or foe?, Nitric Oxide, 10.1016/j.niox.2021.08.006, 116, (27-34), Online publication date: 1-Nov-2021. Wu P, Huang J, Liu Y, Su H, Chen S, Chiu Y and Chang J (2021) Aortic Root Dilatation Is Attenuated with Diabetes but Is Not Associated with Renal Progression in Chronic Kidney Disease, Journal of Personalized Medicine, 10.3390/jpm11100972, 11:10, (972) Arce C, Rodríguez-Rovira I, De Rycke K, Durán K, Campuzano V, Fabregat I, Jiménez-Altayó F, Berraondo P and Egea G (2021) Anti-TGFβ (Transforming Growth Factor β) Therapy With Betaglycan-Derived P144 Peptide Gene Delivery Prevents the Formation of Aortic Aneurysm in a Mouse Model of Marfan Syndrome, Arteriosclerosis, Thrombosis, and Vascular Biology, 41:9, (e440-e452), Online publication date: 1-Sep-2021. Tehrani A, White Z, Milad N, Esfandiarei M, Seidman M and Bernatchez P (2021) Blood pressure‐independent inhibition of Marfan aortic root widening by the angiotensin II receptor blocker valsartan, Physiological Reports, 10.14814/phy2.14877, 9:10, Online publication date: 1-May-2021. Cui J, Harris K, Raedschelders K, Hollander Z, Potts J, De Souza A, Kiess M, McManus B, Bernatchez P, Raffin L, Paine H, van Breemen C, Sandor G and Esfandiarei M (2021) Aortic Dimensions, Biophysical Properties, and Plasma Biomarkers in Children and Adults with Marfan or Loeys-Dietz Syndrome, CJC Open, 10.1016/j.cjco.2020.12.018, 3:5, (585-594), Online publication date: 1-May-2021. Lim W, Corden B, Ng B, Vanezis K, D'Agostino G, Widjaja A, Song W, Xie C, Su L, Kwek X, Tee N, Dong J, Ko N, Wang M, Pua C, Jamal M, Soh B, Viswanathan S, Schafer S and Cook S (2020) Interleukin-11 is important for vascular smooth muscle phenotypic switching and aortic inflammation, fibrosis and remodeling in mouse models, Scientific Reports, 10.1038/s41598-020-74944-7, 10:1, Online publication date: 1-Dec-2020. Boezio G, Bensimon-Brito A, Piesker J, Guenther S, Helker C and Stainier D (2020) Endothelial TGF-β signaling instructs smooth muscle cell development in the cardiac outflow tract, eLife, 10.7554/eLife.57603, 9 Chen P, Qin L, Li G, Malagon-Lopez J, Wang Z, Bergaya S, Gujja S, Caulk A, Murtada S, Zhang X, Zhuang Z, Rao D, Wang G, Tobiasova Z, Jiang B, Montgomery R, Sun L, Sun H, Fisher E, Gulcher J, Fernandez-Hernando C, Humphrey J, Tellides G, Chittenden T and Simons M (2020) Smooth Muscle Cell Reprogramming in Aortic Aneurysms, Cell Stem Cell, 10.1016/j.stem.2020.02.013, 26:4, (542-557.e11), Online publication date: 1-Apr-2020. Liu B, Granville D, Golledge J and Kassiri Z (2020) Pathogenic mechanisms and the potential of drug therapies for aortic aneurysm, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00621.2019, 318:3, (H652-H670), Online publication date: 1-Mar-2020. Stanger O (2020) Die thorakale Aorta Kompendium der modernen Herzchirurgie beim Erwachsenen, 10.1007/978-3-7091-0451-4_12, (211-234), . Jana S, Hu M, Shen M and Kassiri Z (2019) Extracellular matrix, regional heterogeneity of the aorta, and aortic aneurysm, Experimental & Molecular Medicine, 10.1038/s12276-019-0286-3, 51:12, (1-15), Online publication date: 1-Dec-2019. Le Page A, Khalil A, Vermette P, Frost E, Larbi A, Witkowski J and Fulop T (2019) The role of elastin-derived peptides in human physiology and diseases, Matrix Biology, 10.1016/j.matbio.2019.07.004, 84, (81-96), Online publication date: 1-Nov-2019. Raffort J, Lareyre F, Clément M, Moratal C, Jean-Baptiste E, Hassen-Khodja R, Burel-Vandenbos F, Bruneval P, Chinetti G and Mallat Z (2019) Transforming growth factor β neutralization finely tunes macrophage phenotype in elastase-induced abdominal aortic aneurysm and is associated with an increase of arginase 1 expression in the aorta, Journal of Vascular Surgery, 10.1016/j.jvs.2018.09.045, 70:2, (588-598.e2), Online publication date: 1-Aug-2019. Petsophonsakul P, Furmanik M, Forsythe R, Dweck M, Schurink G, Natour E, Reutelingsperger C, Jacobs M, Mees B and Schurgers L (2019) Role of Vascular Smooth Muscle Cell Phenotypic Switching and Calcification in Aortic Aneurysm Formation, Arteriosclerosis, Thrombosis, and Vascular Biology, 39:7, (1351-1368), Online publication date: 1-Jul-2019. Dubacher N, Münger J, Gorosabel M, Crabb J, Ksiazek A, Caspar S, Bakker E, van Bavel E, Ziegler U, Carrel T, Steinmann B, Zeisberger S, Meienberg J and Matyas G (2019) Celiprolol but not losartan improves the biomechanical integrity of the aorta in a mouse model of vascular Ehlers–Danlos syndrome, Cardiovascular Research, 10.1093/cvr/cvz095 Golledge J (2018) Abdominal aortic aneurysm: update on pathogenesis and medical treatments, Nature Reviews Cardiology, 10.1038/s41569-018-0114-9, 16:4, (225-242), Online publication date: 1-Apr-2019. Suzuki T and Sawaki D (2019) Biomarkers of Acute Aortic Syndrome Surgical Management of Aortic Pathology, 10.1007/978-3-7091-4874-7_16, (233-241), . Sawaki D and Suzuki T (2019) Insights into the Pathogenic Mechanisms of Acute Dissection Surgical Management of Aortic Pathology, 10.1007/978-3-7091-4874-7_12, (181-189), . Nogi M, Satoh K, Sunamura S, Kikuchi N, Satoh T, Kurosawa R, Omura J, Elias-Al-Mamun M, Abdul Hai Siddique M, Numano K, Kudo S, Miyata S, Akiyama M, Kumagai K, Kawamoto S, Saiki Y and Shimokawa H (2018) Small GTP-Binding Protein GDP Dissociation Stimulator Prevents Thoracic Aortic Aneurysm Formation and Rupture by Phenotypic Preservation of Aortic Smooth Muscle Cells, Circulation, 138:21, (2413-2433), Online publication date: 20-Nov-2018. Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G and Mallat Z (2018) Diabetes and aortic aneurysm: current state of the art, Cardiovascular Research, 10.1093/cvr/cvy174, 114:13, (1702-1713), Online publication date: 1-Nov-2018. Mecham R (2018) Elastin in lung development and disease pathogenesis, Matrix Biology, 10.1016/j.matbio.2018.01.005, 73, (6-20), Online publication date: 1-Nov-2018. Lin C, Lin C and Stitziel N (2018) Genetics of the extracellular matrix in aortic aneurysmal diseases, Matrix Biology, 10.1016/j.matbio.2018.04.005, 71-72, (128-143), Online publication date: 1-Oct-2018. Craft C, Broekelmann T and Mecham R (2018) Microfibril-associated glycoproteins MAGP-1 and MAGP-2 in disease, Matrix Biology, 10.1016/j.matbio.2018.03.006, 71-72, (100-111), Online publication date: 1-Oct-2018. Michel J, Jondeau G and Milewicz D (2018) From genetics to response to injury: vascular smooth muscle cells in aneurysms and dissections of the ascending aorta, Cardiovascular Research, 10.1093/cvr/cvy006, 114:4, (578-589), Online publication date: 15-Mar-2018. Lino Cardenas C, Kessinger C, MacDonald C, Jassar A, Isselbacher E, Jaffer F and Lindsay M (2018)(2018)(2018)(2018) Inhibition of the methyltranferase EZH2 improves aortic performance in experimental thoracic aortic aneurysm, JCI Insight, 10.1172/jci.insight.97493, 3:5, Online publication date: 8-Mar-2018., Online publication date: 8-Mar-2018., Online publication date: 8-Mar-2018., Online publication date: 8-Mar-2018. Yu C and Jeremy R (2018) Angiotensin, transforming growth factor β and aortic dilatation in Marfan syndrome: Of mice and humans, IJC Heart & Vasculature, 10.1016/j.ijcha.2018.02.009, 18, (71-80), Online publication date: 1-Mar-2018. Sellers S, Milad N, Chan R, Mielnik M, Jermilova U, Huang P, de Crom R, Hirota J, Hogg J, Sandor G, Van Breemen C, Esfandiarei M, Seidman M and Bernatchez P (2018) Inhibition of Marfan Syndrome Aortic Root Dilation by Losartan, The American Journal of Pathology, 10.1016/j.ajpath.2017.11.006, 188:3, (574-585), Online publication date: 1-Mar-2018. Siegert A, Serra-Peinado C, Gutiérrez-Martínez E, Rodríguez-Pascual F, Fabregat I and Egea G (2018) Altered TGF-β endocytic trafficking contributes to the increased signaling in Marfan syndrome, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 10.1016/j.bbadis.2017.11.015, 1864:2, (554-562), Online publication date: 1-Feb-2018. May 26, 2017Vol 120, Issue 11 Advertisement Article InformationMetrics © 2017 The Authors.Circulation Research is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.https://doi.org/10.1161/CIRCRESAHA.116.310371PMID: 28546355 Originally publishedMay 26, 2017 Keywordsaneurysmaortic dissectionaortaconnective tissueextracellular matrixlosartanPDF download Advertisement SubjectsAneurysmAortic DissectionPathophysiologyVascular Biology
Referência(s)